Zura Bio Limited
FSX: 94E.F0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Frankfurt Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sandeep C. Kulkarni
- Employees
- 30
- Headquarters
- San Diego, United States
- IPO year
- 2023
- Market cap
- €248.4M
- Website
- https://zurabio.com
Loading 94E…
Loading profile data…Frequently asked questions about 94E
What does Zura Bio Limited (94E.F) do?
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial de...
Where does 94E.F trade?
Zura Bio Limited (94E.F) trades on the Frankfurt Stock Exchange.
What sector is 94E.F in?
Zura Bio Limited (94E.F) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Zura Bio Limited?
Sandeep C. Kulkarni is the chief executive officer of Zura Bio Limited (94E.F).
Where is Zura Bio Limited headquartered?
Zura Bio Limited is headquartered in United States.
Does 94E.F pay a dividend?
Zura Bio Limited (94E.F) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 94E.F go public?
Zura Bio Limited (94E.F) completed its initial public offering in 2023.